Author: Touré, Alhassane ; Mapan, Koundouno A ; Diallo, Abdourahamane ; Halloran, M Elizabeth ; Henao-Restrepo, Ana Maria ; Sekouba, Kourouma ; Bah, Aissatou ; Diallo, Alpha A ; Gsell, Pierre-Stéphane ; Muyembe, Jean-Jacques ; Litvinova, Maria ; Koundouno, Thérèse ; Doré, Kassié ; Nomou, Alphonse ; Mulangu, Sabué ; Barry, Aissatou ; Bagayoko, Aminata ; Chérif, Mohamed ; Sani, Ismaila ; Lamah, Fassou ; Barry, Fatoumata ; Sy, Mamadou M ; Fall, Ibrahima Socé ; Longini, Ira M ; Condé, Doussou ; Onivogui, Patrice K ; Diakité, Mory ; Maneno, Henry ; Salama, Peter ; Ajelli, Marco ; Bah, Ibrahima ; Soumah, Abdoulaye ; Vespignani, Alessandro ; Diallo, Fatoumata ; Merler, Stefano ; Ryan, Mike J

OBJECTIVESAssess the effectiveness of ring vaccination in controlling an Ebola virus outbreak in the Democratic Republic of Congo.METHODSThis analysis focuses on two areas of the Democratic Republic of Congo, Beni and Butembo/Katwa, which were affected during the 2018-2020 Ebola outbreak. To simulate Ebola virus transmission, we used a spatially explicit agent-based model with households, health care facilities, and Ebola treatment units. Model parameters were calibrated using data collected under the ring-vaccination expanded-access protocol implemented during the outbreak. The model was used to estimate the impact of the deployed ring vaccination strategy, compared to what would have happened if there had been no ring vaccination. The impact of alternative vaccination strategies (mass vaccination, targeted geographic vaccination, and ring-plus) was evaluated as well.RESULTSCompared to a hypothetical scenario where vaccination was not implemented, ring vaccination was estimated to have averted 54.3% (SD, 32.5%) and 62.7% (SD, 23.2%) of potential cases in Beni and Butembo/Katwa, respectively. Under ring vaccination, the average number of averted cases per 1000 vaccine doses administered was 15.1 (SD, 16.8) and 27.8 (SD, 22.9), in Beni and Butembo/Katwa, respectively. In terms of number of averted cases per vaccine dose, ring vaccination was estimated to be more efficient than any of the other evaluated vaccination strategies.CONCLUSIONDespite some level of social instability, ring vaccination with the rVSV-ZEBOV vaccine was highly effective during the 2018-2020 Ebola outbreak in the Democratic Republic of Congo. As compared to alternative vaccination strategies, ring vaccination was estimated to be the most efficient.

100 Deals associated with Further-attenuated rVSV/ZEBOV vaccine(N1)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hemorrhagic Fever, Ebola	Preclinical	US	Profectus BioSciences, Inc.	08 Apr 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Further-attenuated rVSV/ZEBOV vaccine(N1)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation